75 results
8-K
EX-99.1
VRNA
Verona Pharma plc
8 Aug 24
Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
8:44am
expenses and capital expenditure requirements beyond 2026 including the commercial launch of Ohtuvayre in the US.
R&D Expenses: Research and development … research and development expense for the three months ended June 30, 2023.
SG&A Expenses: Selling general and administrative expenses (“SG&A”) were
8-K
EX-99.1
bo5jakplw799ao4wo
9 May 24
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:22am
PRE 14A
7wwl6 r6knus
8 Mar 24
Preliminary proxy
4:18pm
8-K
EX-99.1
1c3ou
29 Feb 24
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
6:08am
8-K
EX-99.1
dsvt3xa 8arud
2 Nov 23
Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
6:24am
8-K
EX-99.1
hucdvwxrbcyd6dnk hp7
3 Aug 23
Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update
6:11am
8-K
EX-99.1
q2d8iragospfim6l
9 May 23
Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
6:13am
8-K
od7s3m6g3 337x
20 Dec 22
Regulation FD Disclosure
6:02am
8-K
EX-99.1
p5pju986zb95k7xzw8do
9 Nov 22
Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update
6:35am